1) Acquire synergistic revenue generating products in biodefense and other specialty markets. This approach is designed to advance the company towards the achievement of the 2015 goals by:
- increasing revenue through product acquisitions addressing specialty markets where existing capabilities can improve product performance and financial returns;
- enhancing contributions to net income growth; and
- providing product revenue diversification.
- advancing only those programs that have achieved clinically important milestones that justify further research and development investments;
- enhancing the value of development expenditures by focusing on products that have the potential for nearer term regulatory approval; and
- minimizing early stage research and development costs that are not funded by third parties.
- mitigating operational risk through the knowledge, capabilities and expertise provided by partners and collaborators; and
- offsetting development expenditures through non-dilutive funding.